Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

105.92 +1.00 (+0.95%)
Official Closing Price Updated: 7:00 PM EDT, Mar 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
46 47 Next >
$100 Invested In Merck & Co 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
The Best And Worst Performing Stocks Of 2022 (Through 12/22)
A look at the best and worst performing Russell 1,000 stocks year-to-date on a total return basis. 
Via Talk Markets
Meta Settles Cambridge Analytica Scandal Case, Microsoft Files Rebuttal To FTC's Lawsuit Against Activision Deal, US Winter Storm Snaps Holiday Plans: Today's Top Stories
Reuters 
Via Benzinga
Merck COVID Antiviral Does Not Reduce Risk Of Hospitalization, Death Rates In Vaccinated Individuals
 
Via Benzinga
Merck, Kelun-Biotech Ink Licensing Pact For Seven Cancer Candidates
 
Via Benzinga
7 Drug Stocks That Will Soar in 2023
These drug stocks to buy look poised to generate huge profits for investors in 2023 and in subsequent years. 
Via InvestorPlace
7 Perfect Presents to Gift Your 2023 Stock Portfolio
As we leave 2022 behind, these hot stocks to buy have significant potential and serious catalysts as we move into New Year 2023. 
Via InvestorPlace
Delta and Moderna Share Good News
We've also got a look at money-related New Year's resolutions. 
Via The Motley Fool
After Disappointing Phase 2 Data, Merck Drops Eye Disease Related Pact With NGM Biopharm
 
Via Benzinga
Could This Opportunity Make Moderna a Hot Buy Again?
Merck and Moderna recently announced positive results from a trial involving their personalized cancer vaccine. 
Via The Motley Fool
Europe Approves AstraZeneca's Two Combo Therapies For Prostate, Bile Duct Cancer Settings
 
Via Benzinga
Gilead Sciences (GILD) Stock Falls on Lung Cancer Drug Data
Although Gilead Sciences produced meaningful results regarding a lung cancer drug test, the competitive shortfall hurt GILD stock. 
Via InvestorPlace
Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says
 
Via Benzinga
Arcus, Gilead Disappoint As Lung-Cancer Regimen Lags Rival Roche
Gilead and Arcus toppled Tuesday after their lung-cancer regimen trailed a rival concoction from Roche. 
Via Investor's Business Daily
2 Smartest Tech Stocks to Buy in 2022 and Beyond
The tech space is still bursting with opportunities for long-term investors. 
Via The Motley Fool
Tuesday Talk: Where is Santa?
Monday continued the downtrend for the major indices on Wall Street which concluded a second week of losses on Friday. As for an annual Santa rally, that seems nowhere to be found. 
Via Talk Markets
Healthcare Portfolio Is Doing Well But Biotech Stocks Are Mired In Macro
The biotech sector has not done well in 2022 despite some strong runs. Small and mid-cap stocks are more “risk-off’ with interest rates rising and sentiment waning. 
Via Talk Markets
What's Going On With Moderna Stock Monday?
Moderna Inc (NASDAQ: MRNA) shares are trading higher Monday following positive analyst coverage from Jefferies.  
Via Benzinga
Are These Multibillion-Dollar Vaccine Stocks Still a Buy?
Moderna and Merck are up on the news regarding their melanoma cancer vaccine. 
Via The Motley Fool
Market Rally Pressured On Fed Rate Outlook; Moderna, Boeing, Tesla In Focus: Weekly Review
Moderna spiked on a cancer vaccine while Tesla continued to dive. 
Via Investor's Business Daily
2 Biotech Stocks to Buy Hand Over Fist in 2023 and 1 to Avoid Like the Plague
Two drug developers stand out as plain-as-day bargains in the new year, while another top-performing biotech stock looks poised to disappoint. 
Via The Motley Fool
20 Dividend Growth Stocks For Faster Growth And Profit
The equal weight growth model was willing to accept faster-growing companies with lower current dividend yields, but faster-growing dividends. 
Via Talk Markets
BioNTech Stock Gets Upgrade, Analyst Sees Multiple Upside Opportunities
 
Via Benzinga
Elon Musk Dumps Another $3.6B Tesla Stock, Facebook's Jobs' Feature To Disappear Next Year, Foxconn Relaxes Covid Restrictions In China Factory: Today's Top Stories
Benzinga Elon Musk Dumps Another $3.6 Billion Of Tesla Stock 
Via Benzinga
2 Dividend Stocks to Buy and Hold Through 2023 and Beyond
These pharma giants are crushing the broader market this year. 
Via The Motley Fool
West Africa-Based Studies Show JNJ, Merck's Ebola Vaccines Provide Lasting Antibodies
 
Via Benzinga
The Best ETF For Dividend Yield And Dividend Growth
This ETF checks off all the boxes in terms of performance, dividend growth, and solid yield. 
Via The Motley Fool
FDA Extends Review Period For AstraZeneca-Merck Partnered Cancer Drug, Lynparza
 
Via Benzinga
Is Moderna a Good Stock to Buy Right Now?
Recent results suggest the company's cancer vaccine candidate can succeed where others have failed. 
Via The Motley Fool
Finding 20 Dividend Growth Stocks In A Bad Market
Starting in 2012, it became more and more difficult for prudent dividend growth stock investors looking for income. The stock market was trading at excessive valuations, and interest rates were at... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
46 47 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.